You are here

Eflornithine Does Not Improve Outcome in Superficial Bladder Cancer

SAN ANTONIO--(BUSINESS WIRE)--Jan. 15, 2004--ILEX(tm) Oncology Inc. (Nasdaq:ILXO - News) announced today that the investigational agent eflornithine (DFMO), which was being studied by ILEX in collaboration with the National Cancer Institute (NCI) in a Phase III placebo-controlled trial of patients with superficial bladder cancer, did not prevent the recurrence of cancer more so than placebo and that the trial has been discontinued. The findings of an independent data monitoring board determined that no statistical significance among the treatment arms was observed.

The NCI is continuing to study the agent in a number of clinical settings.

Source: ILEX Oncology Inc.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only